Cited 9 times in
Efficacy and Safety of Weekly Alendronate Plus Vitamin D₃ 5600 IU versus Weekly Alendronate Alone in Korean Osteoporotic Women: 16-Week Randomized Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문성환 | - |
dc.contributor.author | 박종석 | - |
dc.contributor.author | 임승길 | - |
dc.contributor.author | 김광준 | - |
dc.date.accessioned | 2015-01-06T16:39:51Z | - |
dc.date.available | 2015-01-06T16:39:51Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/98527 | - |
dc.description.abstract | Vitamin D (vit-D) is essential for bone health, although many osteoporosis patients have low levels of 25-hydroxy-vit-D [25(OH)D]. This randomized, open-label study compared the effects of once weekly alendronate 70 mg containing 5600 IU vit-D₃ (ALN/D5600) to alendronate 70 mg without additional vit-D (ALN) on the percent of patients with vit-D insufficiency [25(OH)D <15 ng/mL, primary endpoint] and serum parathyroid hormone (PTH, secondary endpoint) levels in postmenopausal, osteoporotic Korean women. Neuromuscular function was also measured. A total of 268 subjects were randomized. Overall, 35% of patients had vit-D insufficiency at baseline. After 16-weeks, there were fewer patients with vit-D insufficiency in the ALN/D5600 group (1.47%) than in the ALN group (41.67%) (p<0.001). Patients receiving ALN/D5600 compared with ALN were at a significantly decreased risk of vit-D insufficiency [odds ratio=0.02, 95% confidence interval (CI) 0.00-0.08]. In the ALN/D5600 group, significant increases in serum 25(OH)D were observed at weeks 8 (9.60 ng/mL) and 16 (11.41 ng/mL), where as a significant decrease was recorded in the ALN group at week 16 (-1.61 ng/mL). By multiple regression analysis, major determinants of increases in serum 25(OH)D were ALN/D5600 administration, seasonal variation, and baseline 25(OH)D. The least squares mean percent change from baseline in serum PTH in the ALN/D5600 group (8.17%) was lower than that in the ALN group (29.98%) (p=0.0091). There was no significant difference between treatment groups in neuromuscular function. Overall safety was similar between groups. In conclusion, the administration of 5600 IU vit-D in the ALN/D5600 group improved vit-D status and reduced the magnitude of PTH increase without significant side-effects after 16 weeks in Korean osteoporotic patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 715~724 | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Alendronate/adverse effects | - |
dc.subject.MESH | Alendronate/therapeutic use* | - |
dc.subject.MESH | Cholecalciferol/adverse effects | - |
dc.subject.MESH | Cholecalciferol/deficiency | - |
dc.subject.MESH | Cholecalciferol/therapeutic use* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Osteoporosis, Postmenopausal/drug therapy* | - |
dc.subject.MESH | Vitamin D Deficiency/drug therapy* | - |
dc.title | Efficacy and Safety of Weekly Alendronate Plus Vitamin D₃ 5600 IU versus Weekly Alendronate Alone in Korean Osteoporotic Women: 16-Week Randomized Trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Orthopedic Surgery (정형외과학) | - |
dc.contributor.googleauthor | Kwang Joon Kim | - |
dc.contributor.googleauthor | Yong-Ki Min | - |
dc.contributor.googleauthor | Jung-Min Koh | - |
dc.contributor.googleauthor | Yoon-Sok Chung | - |
dc.contributor.googleauthor | Kyoung Min Kim | - |
dc.contributor.googleauthor | Dong-Won Byun | - |
dc.contributor.googleauthor | In Joo Kim | - |
dc.contributor.googleauthor | Mikyung Kim | - |
dc.contributor.googleauthor | Sung-Soo Kim | - |
dc.contributor.googleauthor | Kyung Wan Min | - |
dc.contributor.googleauthor | Ki Ok Han | - |
dc.contributor.googleauthor | Hyoung Moo Park | - |
dc.contributor.googleauthor | Chan Soo Shin | - |
dc.contributor.googleauthor | Sung Hee Choi | - |
dc.contributor.googleauthor | Jong Suk Park | - |
dc.contributor.googleauthor | Dong Jin Chung | - |
dc.contributor.googleauthor | Ji Oh Mok | - |
dc.contributor.googleauthor | Hong Sun Baek | - |
dc.contributor.googleauthor | Seong-Hwan Moon | - |
dc.contributor.googleauthor | Yong Soo Kim | - |
dc.contributor.googleauthor | Sung-Kil Lim | - |
dc.identifier.doi | 10.3349/ymj.2014.55.3.715 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01365 | - |
dc.contributor.localId | A03375 | - |
dc.contributor.localId | A00317 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 24719139 | - |
dc.subject.keyword | Alendronate | - |
dc.subject.keyword | osteoporosis | - |
dc.subject.keyword | parathyroid hormone | - |
dc.subject.keyword | vitamin-D | - |
dc.subject.keyword | vitamin-D insufficiency | - |
dc.contributor.alternativeName | Moon, Seong Hwan | - |
dc.contributor.alternativeName | Park, Jong Suk | - |
dc.contributor.alternativeName | Lim, Sung Kil | - |
dc.contributor.affiliatedAuthor | Moon, Seong Hwan | - |
dc.contributor.affiliatedAuthor | Lim, Sung Kil | - |
dc.contributor.affiliatedAuthor | Kim, Kwang Joon | - |
dc.citation.volume | 55 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 715 | - |
dc.citation.endPage | 724 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.55(3) : 715-724, 2014 | - |
dc.identifier.rimsid | 57649 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.